ID Source | ID |
---|---|
PubMed CID | 29216 |
CHEMBL ID | 1890813 |
CHEBI ID | 6803 |
SCHEMBL ID | 66434 |
MeSH ID | M0058558 |
Synonym |
---|
n-(2-benzothiazolyl)-n,n'-dimethylurea |
methabenzthiazuron |
18691-97-9 |
NCGC00163728-01 |
tribunil |
bay 74283 |
einecs 242-505-0 |
brn 0196633 |
urea, 1-(2-benzothiazolyl)-1,3-dimethyl- |
n-2-benzothiazolyl-n,n'-dimethylurea |
ccris 6766 |
1,3-dimethyl-3-(2-benzthiazolyl)-harnstoff [german] |
bayer 5633 |
1-(2-benzothiazolyl)-1,3-dimethylurea |
epa pesticide chemical code 281300 |
methbenzthiazuron |
caswell no. 081b |
preparation 5633 |
metabenzthiazuron |
n-methyl-n'-methyl-n'-(2-benzothiazolyl)urea |
methabenzthiazuron [bsi:iso] |
1,3-dimethyl-3-(2-benzothiazolyl)urea |
1-benzothiazol-2-yl-1,1'-dimethylurea |
s 25128 |
FT-0656502 |
inchi=1/c10h11n3os/c1-11-9(14)13(2)10-12-7-5-3-4-6-8(7)15-10/h3-6h,1-2h3,(h,11,14) |
rrviaqkbtuqodi-uhfffaoysa- |
1-(1,3-benzothiazol-2-yl)-1,3-dimethylurea |
NCGC00163728-02 |
urea, n-2-benzothiazolyl-n,n'-dimethyl- |
unii-82npf43p0x |
1,3-dimethyl-3-(2-benzthiazolyl)-harnstoff |
82npf43p0x , |
4-27-00-04842 (beilstein handbook reference) |
dtxcid8017570 |
tox21_300966 |
cas-18691-97-9 |
dtxsid0037570 , |
NCGC00254869-01 |
A813097 |
1-(1,3-benzothiazol-2-yl)-1,3-dimethyl-urea |
1-(benzothiazol-2-yl)-1,3-dimethylurea |
AKOS015913141 |
SCHEMBL66434 |
chebi:6803 , |
CHEMBL1890813 |
methabenzthiazuron [iso] |
methabenzthiazuron [mi] |
tribunil (bayer) |
bayer 74283 |
bayer 5653 |
RRVIAQKBTUQODI-UHFFFAOYSA-N |
methibenzuron |
bay 5653 |
bay 72483 |
(benzothiazol-2-yl)-1,3-dimethylurea |
n-(1,3-benzothiazol-2-yl)-n,n'-dimethylurea # |
methabenzthiazuron, pestanal(r), analytical standard |
methabenzthiazuron 100 microg/ml in acetonitrile |
methabenzthiazuron 10 microg/ml in acetonitrile |
J-012018 |
M2334 |
mfcd00055498 |
Q15632903 |
1-(benzo[d]thiazol-2-yl)-1,3-dimethylurea |
D91591 |
BS-44136 |
Class | Description |
---|---|
benzothiazoles | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 35.5742 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 6.2878 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
AR protein | Homo sapiens (human) | Potency | 20.9168 | 0.0002 | 21.2231 | 8,912.5098 | AID1259381; AID743035; AID743036; AID743042; AID743054; AID743063 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 21.6899 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 14.9652 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 54.4827 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 25.1189 | 0.0002 | 14.3764 | 60.0339 | AID588532 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 7.2702 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 30.6304 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 18.7048 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 37.6531 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 5.6841 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743079; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 39.8107 | 0.0010 | 24.5048 | 61.6448 | AID588535 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 28.9172 | 0.0007 | 23.0674 | 1,258.9301 | AID651777; AID743085; AID743122 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 2.1690 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 1.2026 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 21.8799 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743219 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 2.4337 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.6113 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 2.4337 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 62.3263 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
Ataxin-2 | Homo sapiens (human) | Potency | 61.1306 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (21.43) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (42.86) | 29.6817 |
2010's | 5 (35.71) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.82) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 17 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |